Schreiner MediPharm launches Digital Display Label

Schreiner MediPharm has launched the Digital Display Label for digitalizing investigational drugs in clinical trials, helping to eliminate the need for time-consuming manual relabeling.

According to Schreiner, clinical trials entail exacting requirements, including crucial flexibility, speed and precision. Changes to protocol numbers, patient groups, expiration dates and regulatory modifications require manual relabeling of the investigational drugs in many countries, which causes delays and costs.  

The new digital label is based on a modular, reusable plastic housing that protects sensitive display electronics. A conceived adapter system ensures ease of application to various packaging forms. Additional features such as light protection or blinding can be integrated with transparent containers.

A major benefit of the new product is the possibility of updating label information digitally and in real time. As a result, patients and clinical staff always receive current information about the investigational drug without delays and without any additional investment of materials and logistic effort. That enhances patient safety and minimizes the risk of discontinuing clinical trials due to incorrect or obsolete markings.

The new label is compelling regarding sustainability: both the housing and the adapter system are reusable, conserving resources and avoiding waste. The modular design enables integration into existing standard packaging without requiring modifications. At the same time, the system ensures a reliable connection between the Digital Display Label and the primary container or packaging.